ASRS 2024: Topics attendees are keeping an eye on

Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Jennifer I. Lim, MD, FARVO, FASRS:

I'm really looking forward to hearing about the new phase 1 and phase 2 studies looking at these novel treatments for diabetic retinopathy, as well as for age-related macular degeneration. I think our future is really bright. There's a lot of innovation, there are a lot of new mechanisms of action that are being tested. And I think these will give us not only better efficacy, hopefully in the future and the treatments of the diseases, but also improved durability.

Danny Mammo, MD:

You know, we're in this age, we have great injections to treat retinal disease, and I'm looking forward to hearing about newer research on options that are going to give us more durability, such as longer acting injections, or gene therapy. Those are always exciting talks.

Carl Danzig, MD:

I'm looking forward to gene therapy treatments for neovascular AMD. We have a lot of players in this space, and there's a lot of good data being presented. And I'm really excited for what this offers our patients moving forward.